» Articles » PMID: 24622680

Lung Transplantation: a Treatment Option in End-stage Lung Disease

Overview
Date 2014 Mar 14
PMID 24622680
Citations 37
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Lung transplantation is the final treatment option in the end stage of certain lung diseases, once all possible conservative treatments have been exhausted. Depending on the indication for which lung transplantation is performed, it can improve the patient's quality of life (e.g., in emphysema) and/ or prolong life expectancy (e.g., in cystic fibrosis, pulmonary fibrosis, and pulmonary arterial hypertension). The main selection criteria for transplant candidates, aside from the underlying pulmonary or cardiopulmonary disease, are age, degree of mobility, nutritional and muscular condition, and concurrent extrapulmonary disease. The pool of willing organ donors is shrinking, and every sixth candidate for lung transplantation now dies while on the waiting list.

Method: We reviewed pertinent articles (up to October 2013) retrieved by a selective search in Medline and other German and international databases, including those of the International Society for Heart and Lung Transplantation (ISHLT), Eurotransplant, the German Institute for Applied Quality Promotion and Research in Health-Care (Institut für angewandte Qualitätsförderung und Forschung im Gesundheitswesen, AQUA-Institut), and the German Foundation for Organ Transplantation (Deutsche Stiftung Organtransplantation, DSO).

Results: The short- and long-term results have markedly improved in recent years: the 1-year survival rate has risen from 70.9% to 82.9%, and the 5-year survival rate from 46.9% to 59.6%. The 90-day mortality is 10.0%. The postoperative complications include acute (3.4%) and chronic (29.0%) transplant rejection, infections (38.0%), transplant failure (24.7%), airway complications (15.0%), malignant tumors (15.0%), cardiovascular events (10.9%), and other secondary extrapulmonary diseases (29.8%). Bilateral lung transplantation is superior to unilateral transplantation (5-year survival rate 57.3% versus 47.4%).

Conclusion: Seamless integration of the various components of treatment will be essential for further improvements in outcome. In particular, the follow-up care of transplant recipients should always be provided in close cooperation with the transplant center.

Citing Articles

Silicosis: from pathogenesis to therapeutics.

Yang B, Liu X, Peng C, Meng X, Jia Q Front Pharmacol. 2025; 16:1516200.

PMID: 39944632 PMC: 11813918. DOI: 10.3389/fphar.2025.1516200.


Navigating Pediatric Cor Pulmonale: A Comprehensive Review of Diagnosis and Management.

Thakur Y, Meshram R, Taksande A Cureus. 2024; 16(8):e67782.

PMID: 39323679 PMC: 11422785. DOI: 10.7759/cureus.67782.


Comparison of the Effects of Multiple Frailty and Nutritional Indexes on Postoperative Outcomes in Critically Ill Patients Undergoing Lung Transplantation.

Lee S, Lee D, Choi D Medicina (Kaunas). 2024; 60(7).

PMID: 39064447 PMC: 11279017. DOI: 10.3390/medicina60071018.


Different Levels of Autophagy Activity in Mesenchymal Stem Cells Are Involved in the Progression of Idiopathic Pulmonary Fibrosis.

Tao H, Lv Q, Zhang J, Chen L, Yang Y, Sun W Stem Cells Int. 2024; 2024:3429565.

PMID: 38390035 PMC: 10883747. DOI: 10.1155/2024/3429565.


Analysis on the change of gut microbiota and metabolome in lung transplant patients.

Hou Z, Zhang T, Ding Z, Qian T, Wang P, Wu B Microbiol Spectr. 2024; 12(4):e0314223.

PMID: 38385646 PMC: 10986604. DOI: 10.1128/spectrum.03142-23.


References
1.
Keating D, Levvey B, Kotsimbos T, Whitford H, Westall G, Williams T . Lung transplantation in pulmonary fibrosis: challenging early outcomes counterbalanced by surprisingly good outcomes beyond 15 years. Transplant Proc. 2009; 41(1):289-91. DOI: 10.1016/j.transproceed.2008.10.042. View

2.
Mason D, Rajeswaran J, Li L, Murthy S, Su J, Pettersson G . Effect of changes in postoperative spirometry on survival after lung transplantation. J Thorac Cardiovasc Surg. 2012; 144(1):197-203. DOI: 10.1016/j.jtcvs.2012.03.028. View

3.
See V, Roberts-Thomson K, Stevenson W, Camp P, Koplan B . Atrial arrhythmias after lung transplantation: epidemiology, mechanisms at electrophysiology study, and outcomes. Circ Arrhythm Electrophysiol. 2009; 2(5):504-10. DOI: 10.1161/CIRCEP.109.867978. View

4.
Smits J, van der Bij W, Van Raemdonck D, de Vries E, Rahmel A, Laufer G . Defining an extended criteria donor lung: an empirical approach based on the Eurotransplant experience. Transpl Int. 2010; 24(4):393-400. DOI: 10.1111/j.1432-2277.2010.01207.x. View

5.
Smits J, Nossent G, de Vries E, Rahmel A, Meiser B, Strueber M . Evaluation of the lung allocation score in highly urgent and urgent lung transplant candidates in Eurotransplant. J Heart Lung Transplant. 2010; 30(1):22-8. DOI: 10.1016/j.healun.2010.08.006. View